In yesterday’s Wall Street session, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares traded at $40.00, down -23.75% from the previous session.
As of this writing, 15 analysts cover Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $156.00 and a low of $76.00, we find $100.00. Given the previous closing price of $52.46, this indicates a potential upside of 90.62 percent. APLS stock price is now -54.33% away from the 50-day moving average and -39.84% away from the 200-day moving average. The market capitalization of the company currently stands at $4.74B.
There are 3 analysts who have given it a hold rating, whereas 11 have given it a buy rating. Brokers who have rated the stock have averaged $102.64 as their price target over the next twelve months.
With the price target reduced from $83 to $58, Wells Fargo Downgraded its rating from Overweight to Equal Weight for Apellis Pharmaceuticals Inc. (NASDAQ: APLS).
In other news, Machiels Alec, Director sold 1,250 shares of the company’s stock on Jul 17. The stock was sold for $80,988 at an average price of $64.79. Upon completion of the transaction, the Director now directly owns 267,641 shares in the company, valued at $10.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 10, Chief Scientific Officer Deschatelets Pascal sold 12,000 shares of the business’s stock. A total of $1,014,600 was realized by selling the stock at an average price of $84.55. This leaves the insider owning 1,046,813 shares of the company worth $41.87 million. Insiders disposed of 1,768,320 shares of company stock worth roughly $70.73 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in APLS stock. A new stake in Apellis Pharmaceuticals Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $75,189,000. ORBIMED ADVISORS LLC invested $36,408,000 in shares of APLS during the first quarter. In the first quarter, PERCEPTIVE ADVISORS LLC acquired a new stake in Apellis Pharmaceuticals Inc. valued at approximately $22,214,000. FIERA CAPITAL CORP acquired a new stake in APLS for approximately $21,615,000. LAURION CAPITAL MANAGEMENT LP purchased a new stake in APLS valued at around $14,974,000 in the second quarter. In total, there are 363 active investors with 89.80% ownership of the company’s stock.
Tuesday morning saw Apellis Pharmaceuticals Inc. (NASDAQ: APLS) opened at $53.89. During the past 12 months, Apellis Pharmaceuticals Inc. has had a low of $42.15 and a high of $94.75. As of last week, the company has a debt-to-equity ratio of 1.08, a current ratio of 6.90, and a quick ratio of 6.30. The fifty day moving average price for APLS is $86.69 and a two-hundred day moving average price translates $66.37 for the stock.
The latest earnings results from Apellis Pharmaceuticals Inc. (NASDAQ: APLS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$1.56, missing analysts’ expectations of -$1.46 by -0.1. This compares to -$1.42 EPS in the same period last year. The company reported revenue of $44.85 million for the quarter, compared to $14.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 211.84 percent. For the current quarter, analysts expect APLS to generate $66.13M in revenue.
Apellis Pharmaceuticals Inc.(APLS) Company Profile
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
